Trials / Completed
CompletedNCT01718990
Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis
Prospective, Longitudinal Cohort Trial of Patients With Idiopathic Pulmonary Fibrosis (IPF) and Healthy Control Patients. Clinical Data, Blood, and Bronchiolavage (BAL) Fluid Will be Collected Over 12 Months.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 110 (actual)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- 35 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
Drug discovery can take many years especially since most studies to measure effectiveness depend on clinical outcomes like pulmonary function tests and hospitalizations. This is an observational study designed to collect information, blood, and bronchoalveolar lavage fluid in people who have IPF and those who do not. The people who have IPF will be followed for 12 months to collect more biological samples and record clinically relevant information. The goal of this study is to identify new molecular markers that are measurable and reliable in people who have IPF. It is hoped that these markers can be used in future drug studies to significantly speed up the process of finding drugs that help.
Conditions
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2018-06-30
- Completion
- 2018-12-31
- First posted
- 2012-11-01
- Last updated
- 2020-07-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01718990. Inclusion in this directory is not an endorsement.